Tag Archives: Biospace

Phase III Gantenerumab Trial for Prodromal Alzheimer’s Disease Discontinued (Biospace Inc)

Summary The Scarlet RoAD study (a Phase III trial), researching the anti-amyloid drug Gantenerumab for the possible treatment of prodromal (pre-dementia) Alzheimer’s Disease, has been abandoned following disappointing results. Gantenerumab-related research (in a different Phase III investigation) is still underway … Continue reading

Posted in For Doctors (mostly), For Researchers (mostly), In the News, International, Pharmacological Treatments, Quick Insights | Tagged , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Fixed-Dose Combination of Memantine Extended Release and Donepezil for Alzheimer’s Disease: Licensing Application Submitted to FDA (Biospace Inc.)

Summary A new drug application has been submitted to the FDA (in the United States) for a fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer’s Disease dementia. “Using the two drugs together … Continue reading

Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Pharmacological Treatments, Quick Insights | Tagged , , , , , , , , , , , , , , , , , , , , , | Leave a comment